Granulomatous hepatitis associated with etanercept therapy

Area of Science:

• Rheumatology
• Hepatology
• Immunology

Background:

• Etanercept is a biologic therapy used for rheumatoid arthritis and other inflammatory conditions.
• Tumor necrosis factor-alpha (TNF-α) inhibitors like etanercept have been associated with granulomatous reactions.
• The potential for etanercept to induce granulomatous hepatitis has not been previously documented.

Observation:

• A patient with rheumatoid arthritis developed abnormal liver enzymes and was diagnosed with granulomatous hepatitis.
• Other potential causes of liver disease, including infections and metabolic disorders, were ruled out.
• Liver biopsy findings were not characteristic of sarcoidosis, a common cause of granulomas.

Findings:

• The patient's liver enzyme abnormalities resolved after discontinuing etanercept therapy.
• This clinical course suggests a direct link between etanercept use and the development of granulomatous hepatitis.
• The case adds to a growing body of evidence linking etanercept to rare granulomatous reactions.

Implications:

• Clinicians should consider granulomatous hepatitis in patients on etanercept therapy presenting with unexplained liver abnormalities.
• This case highlights a rare but serious potential adverse effect of etanercept.
• Further research may be warranted to elucidate the mechanisms underlying etanercept-induced granulomatous reactions.